Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Author's Avatar
Feb 15, 2022

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the closing of its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55.00 per share, including the exercise in full by the underwriters of their option to purchase up to an additional 681,818 shares of common stock in the offering.Twist estimates net proceeds from the offering to be approximately $269.4 million, after deducting the underwriting discount and commissions and estimated offering expenses.